2	The diagnostic role of abductor pollicis brevis -first dorsal
3	interosseous (APB-FDI) index in diagnosing Amyotrophic lateral
4	sclerosis (ALS) and comparison of its diagnostic performance with
5	other tests demonstrating split hand phenomenon among
6	Bangladeshi population
7	Md. Shuktarul Islam ¹ , Hashmi Sina ² , Iftikher Alam ² , Md. Arifuzzaman ² , Reaz Mahmud ^{2*}
8	1. National Institute of Neurosciences and Hospital
9	2. Department of Neurology, Dhaka Medical College, Dhaka
10	* Corresponding author
11	Mail- reazdmc22@yahoo.com
12	Acknowledgement: Patients who participate.
13	Conflict of Interest
14	The authors declare that there is no conflict of interests regarding the publication of this paper
15	Research number: ERC-SSMC/2019/224.
16	Funding: Received no funds from any source.
17	
18	

19

The diagnostic role of abductor pollicis brevis -first dorsal interosseous (APB-FDI) index in diagnosing Amyotrophic lateral sclerosis (ALS) and comparison of its diagnostic performance with other tests demonstrating split hand phenomenon among Bangladeshi population

24 Abstract

25 Background:

The split hand phenomenon is an early and distinctive feature of amyotrophic lateral sclerosis (ALS), resulting from the differential wasting of the intrinsic hand muscles, particularly the thenar muscles. This study aimed to assess the diagnostic role of the APB-FDI Index in the diagnosis of Amyotrophic Lateral Sclerosis (ALS) among the Bangladeshi population. We also compared its diagnostic performances with FDI-ADM and ADM-APB ratios measuring the split hand phenomenon.

Methods: We carried out this cross-sectional study in the Department of Neurology, Sir 32 Salimullah Medical College Mitford Hospital, and Dhaka Medical College Hospital, Dhaka, from 33 March 2019 to September 2021. We determined the APB-FDI index with APB (CMAP) X FDI 34 35 (CMAP) /ADM (CMAP). We also compared the findings with age and gender-matched healthy control and disease control (Hirayama disease). We studied the value of using APB-FDI, FDI-36 ADM, and ADM-APB ratios for diagnosis. We analyzed the data with ROC curves and calculated 37 AUC for each ratio. We also used IDI and DCA to compare diagnostic accuracy. 38 **Results:** 39

40	We studied 43 people with ALS, 30 healthy people, and 10 Hirayama patients. Most ALS patients
41	had cervical phenotypes (31, 72%) and a median ALS functional rating score of 27(IQR,25-32).
42	The cutoff values of APB-FDI Index, ADM-APB CMAP amplitude ratio, and FDI-ADM CMAP
43	amplitude ratio are 4.27, 2.20 respectively. The APB-FDI Index has a high AUC of 0.9, with good
44	sensitivity and specificity. However, for Hirayama disease, the APB-FDI Index cutoff value is
45	11.6. The APB-FDI Index is clinically effective with optimal threshold probabilities identified
46	through the Youden-Index ((APB-FDI Index-0.72, ADM-APB CMAP amplitude ratio-0.51, and
47	FDI-ADM CMAP amplitude ratio-0.17). Its standardized net benefits exceed healthy control and
48	Hirayama when risk thresholds are between 0.1 and 0.8. The IDI results showed that the APB-FDI
49	Index was superior to the ADM-APB CMAP amplitude ratio and FDI-ADM CMAP amplitude
50	ratio in healthy control and Hirayama although p value is insignificant.
51	Conclusion: APB-FDI Index is the sensitive, specific, and early diagnostic marker for ALS. Its
52	diagnostic performance is better than the other tests.
53	Keywords: amyotrophic lateral sclerosis; compound muscle action potential; split hand; APB-FDI
54	index.
55	
56	
57	
58	
59	
60	

The diagnostic role of abductor pollicis brevis -first dorsal interosseous (APB-FDI) index in diagnosing Amyotrophic lateral sclerosis (ALS) and comparison of its diagnostic performance with other tests demonstrating split hand phenomenon among Bangladeshi population

65 Introduction:

Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disorder [1] involving the 66 motor neurons, a heterogeneous disease that begins focally and becomes widespread within a short 67 period. The patient dies within three years of symptom onset due to respiratory muscle 68 involvement [2]. The mechanisms of neuronal degeneration include oxidative stress, 69 excitotoxicity, mitochondrial dysfunction, glial activation, RNA processing, and growth factor 70 71 abnormalities. They may occur parallelly or in sequence [3]. There is no definitive diagnostic tool for diagnosing ALS. The progressive upper motor neuron (UNM) and lower motor neuron (LMN) 72 findings in the history and examination may diagnose ALS with 95% accuracy [4]. For the 73 uniformity of the diagnosis, El Escorial criteria were developed [5,6]. The sensitivity of these 74 75 criteria is low in case of early stages of the disease [7]. Possible differentials like Spinal muscular atrophy (SMA), Hirayama disease, cervical myeloradiculopathy, and Multifocal motor neuropathy 76 with conduction block (MMCB) are sometimes difficult to exclude [8]. The median diagnostic 77 time from the symptom onset is 11.5 months, and about half of the patients received alternative 78 diagnoses [9]. A dissociated pattern of muscle atrophy, first described as a split hand by Wilbourn 79 [10], was observed in 60-70 % of ALS patients [9,11]. Here the abductor pollicis brevis (APB) 80 and first dorsal interosseous (FDI) muscles are involved more than the hypothenar muscles. The 81 cause of differential muscle involvement in ALS is unknown; there are theories for cortical and 82

peripheral mechanisms.[12] Among the postulated peripheral mechanism, higher nodal
persistence of sodium currents in the APB and FDI than in ADM might be a mechanism [13].
Furthermore, the cortical mechanism involves preferential involvement of corticomotoneuronal
input to the thenar muscles [14]. In our day-to-day activities, using a pincer grasp is essential
(adductor pollicis, first dorsal interosseous and flexor pollicis brevis muscles.), making the spinal
motor neurons innervating these muscles liable to more oxidative stress.

The corticospinal connections to FDI far outnumber those of ADM. It may produce more 89 glutamate excitotoxicity in the FDI spinal neurons [15]. The APB-FDI index quantifies this 90 preferential muscle involvement, which is derived by multiplying the APB and FDI CMAP 91 amplitudes and dividing the product by the ADM CMAP amplitude according to the following 92 formula: (APB FDI Index = $\frac{APB_{CMAP \times FDI_{CMAP}}}{ADM_{CMAP}}$ [16]. This index helps detect the early stages of ALS, 93 not fulfilling the diagnostic criteria [11]. This phenomenon did not differ in different stages and 94 certainty [17]. The cutoff value of this index is 5.2 and exhibits 74% sensitivity and 80% specificity 95 in diagnosing ALS [11]. It is more sensitive than the two other ratios used to quantify the split 96 hand phenomenon (ADM/APB CMAP amplitude ratio >1.7, 51% sensitive, and FDI/ADM less 97 than 0.9 is 34 % sensitive) [16]). This method was not examined among the Bangladeshi 98 population, and the cutoff value is largely unknown among the Bangladeshi people. We planned 99 to assess the diagnostic role of the APB FDI Index, ADM/APB CMAP amplitude ratio, and 100 101 FDI/ADM CMAP amplitude ratio in the diagnosis of Amyotrophic Lateral Sclerosis (ALS) and to determine their cutoff values for the Bangladeshi population. We also compared their diagnostic 102 performance in diagnosing ALS. 103

104

105 Methods:

This cross-sectional study was done in the Department of Neurology at Sir Salimullah Medical
College Mitford Hospital, Dhaka, and Dhaka Medical College from March 2019 to September
2020. We obtained Ethical clearance from the ethical review committee of Sir Salimullah Medical
College Mitford Hospital (SSMC/2019/224).

110 **Participants:**

We enrolled all the probable, possible, and definite cases of Amyotrophic lateral sclerosis (ALS), 111 according to the revised El Escorial Diagnostic Criteria for ALS [5], presented in 112 electrophysiology lab of the neurology department of Sir Salimullah Medical College Mitford 113 Hospital and Dhaka Medical College. Patients aged 18 years or more and of both sexes were 114 included in this study. Patients with undetectable CMAP amplitude of any muscle (APB, FDI, and 115 ADM), associated radiculopathy, peripheral neuropathy, or neuromuscular disease were excluded 116 117 from the study. We recruited healthy volunteers as the control. We also took patients with Hirayama disease, diagnosed according to criteria outlined by Tashiro et al[18]. and confirmed 118 with MRI cervical spine flexion and extension view as disease control. Both the cases and control 119 participants gave Informed written consent. The calculated sample size was 30 for ALS and 120 healthy-control, considering the abnormal split hand index proportion of 41% in the case and 5% 121 in the healthy control group, according to Kuwabara et al. 2008[19]. With a 5% level of 122 significance in the two-tailed test and 90% power. We used the following formula to calculate the 123 sample size 124

125 Sample size
$$= \left(\frac{r+1}{r}\right) \frac{P(1-p)(z_{\beta}+Z_{\alpha/2})^2}{(p_1-p_2)^2}$$

126 $(Z_{\alpha} = 1.96 \text{ at } 5\% \text{ level of significance, } Z_{\beta} = 1.28 \text{ at } 90\% \text{ power, } P_1 = 0.41 P_2 = 0.05, P = (p_1 + p_2)$ 127 $\div 2 = 0.23$).

128 We also compared the electrophysiology findings of 10 Hirayama patients with the ALS patients.

129 Study procedure:

The demographic profile and complaints were recorded in a preformed case record form. The expert neurologist did detail Neurologic examinations. The hemoglobin, total count, differential count, blood sugar, serum creatinine, brain CT scan, and MRI cervical spine were done to exclude the other diagnoses for all the included patients. Revised El Escorial Diagnostic Criteria for ALS diagnose patients with ALS [5]. The disability of ALS was assessed with ALS Functional Rating Scale-Revised (ALS-FRS-R) [20]. The Hirayama disease was diagnosed with Tashiro criteria [18].

137 NCS assessment:

The NCS was done with NIHON KOHDEN Neuropack MEB-7102 mobile unit with a two-138 channel evoked potential/EMG measuring system (Nihon Kohden Corporation, Tokyo, Japan) 139 according to the American Association of Electrodiagnostic Medicine, American Academy of 140 Neurology, and American Academy of Physical Medicine and Rehabilitation guidelines. We 141 maintained the temperature at 33-34 degrees centigrade. We did the neurophysiological study on 142 the most affected hand and opposite lower limb in cervical onset MND, including the measurement 143 of motor conduction velocity (MCV), distal motor latency (DML), and compound muscle action 144 potential amplitude (CMAP), F-latency, sensory conduction velocity (SCV), distal latency and 145 sensory nerve action potential amplitude (SNAP) of the examined nerves. In limb onset type MND, 146

147 we did the electrophysiological study on the most affected lower limb and opposite upper limb,

and in bulbar onset MND in the right hand and left leg.

149 Motor nerve conduction studies were performed on the median and ulnar nerves with compound 150 muscle action potential (CMAP) responses recorded from the abductor pollicis brevis (APB), first dorsal interosseous (FDI), and abductor digit minimi (ADM) muscles. The Responses were 151 152 recorded by 10 mm gold disc electrodes positioned in a belly tendon arrangement over each muscle. We Placed the active electrode over the midpoint of the respective muscle, ensuring a 153 negative take-off of the CMAP response, while the reference electrode was positioned over the 154 base of the thumb (APB and FDI CMAP recordings) and base of digit 5 (for ADM CMAP 155 recordings). We Set the distance between the stimulating cathode and active electrode for APB 156 and ADM, CMAP to 5 cm, and for FDI CMAP to 8 cm. We set the filter at 3 and 10 kHz, the 157 sweep speed at 20 msec, or 2 msec/division, and the sensitivity for recording CMAP responses at 158 5 mV. The pulse duration was 0.2 ms. We increased an additional 25% in the current to ensure the 159 Supramaximal stimulation. Measurements of the compound muscle action potential (CMAP) 160 included latency (onset and peak) and conduction velocity (CV). In the study, we used belly tendon 161 montage, gave the stimulation at the wrist using an orthodromic technique with a bipolar 162 163 stimulator, and expressed the distal latency as a millisecond and conduction velocity as a meter per second. 164

We Calculated the APB FDI index by multiplying the CMAP amplitude recorded over the APB and FDI muscles and dividing this product by the CMAP amplitude recorded over the ADM muscle, as follows: APB FDI sindex = APB CMAP X FDI CMAP /ADM CMAP. We also calculated ADM/APB CMAP amplitude ratio, and FDI/ADM CMAP amplitude ratio. For the

analysis, we took the values from the most affected hand in the case of ALS and Hirayama disease.In the case of control, we generally use right-hand parameters.

171

172 Statistical analysis:

Data were analyzed using SPSS 20 and R (v4.1.1). Qualitative data were expressed in number, 173 percentage, normally distributed quantitative data as mean (SD), and non-normal data as median 174 (IQR). Comparisons between groups (continuous parameters) were made by Student's t-test and 175 skewed parameters with Mann Whitney U test. The Chi-Square test compared categorical 176 parameters. Several indicators were used to measure the performance of the APB-FDI Index, FDI-177 ADM, and ADM-APB ratios. The prediction scoring systems were analyzed using the receiver 178 operating characteristic (ROC) curve and the area under the ROC curves (AUC). DeLong's test 179 was used to determine the statistical difference between AUCs. The Integrated Discrimination 180 Improvement (IDI) indicator was also used to evaluate their performance. Decision Curve Analysis 181 (DCA) was also performed to assess the clinical usefulness of these ratios. The significance of the 182 results, as determined by a 95% confidence interval and a value of p < 0.05, was considered 183 statistically significant. 184

185 Results:

This cross-sectional study was conducted in the Neurology department of Sir Salimullah Medical College Mitford Hospital and Dhaka Medical College, Dhaka, from March 2019 to March 2022.
We screened 57 suspected patients with ALS and included 43 patients after considering the patient's inclusion, exclusion criteria, and consent. We had 30 age and sex-matched healthy control

- 190 (Figure 1). We also included 10 Hirayama patients to compare the index and the ratios (APB-FDI
- 191 Index, ADM-APB CMAP amplitude ratio, and FDI-ADM CMAP amplitude ratio)
- 192 Figure 1: Patients and volunteer selection for this study.

Demographic and clinical profile of the participants:

- 194 The age of the ALS group was generally >40 years (88.4%), and the mean age (SD) was 56.1(14.8).
- 195 The age of patients with ALS was comparable with the control. Whereas the Hirayama patients
- were generally < 40 years (90%), and the mean age was 24.7(13.7). The males were similarly
- 197 frequent in ALS, 34(79.1), and Hirayama groups, 7(70%). 15(34.4%) of the ALS patients were
- underweight. The mean (SD) weight of the ALS and Hirayama was 18.8(1.8) and 21.6(2.2),
- respectively (Table 1).
- 200

201 Table 1: Demographic characteristics of the study participants

202

Trait	Group 1	Group	Group III
	(cases)	II(Control)	(Hirayama)
	N=43	N=30	N=10
Age in years, mean (SD)	56.1(14.8)	57.7(9.7)	24.7(13.7)
Age groups, n (%)			
<40 years	5(11.6)	2(6.7)	9(90)
40-60 years	22(51.2)	21(70)	0(0)
>60 years	16(37.2)	7(23.3)	1(10)

Sex (Male), n (%)	34(79.1)	22(73.3)	7(70)
BMI, Mean (SD)	18.8(1.8)	22.8(1.65)	21.6(2.2)
BMI groups, n (%)			
Underweight (<18.5 kg/m ²)	15(34.9)	0(0)	1(10)
Normal weight (18.5-22.9 kg/m ²)	21(48.8)	18(60)	7(70)
Overweight (23-24.9 kg/m ²)	6(14)	11(36.7)	1(10)
Obesity (25-29.9 Kg/m ²)	1(2.3)	1(3.3)	1(10)

203

In this study total of 28(65.1) had definite ALS and presented with median (IQR), 6(5-10) months

of illness. They were generally cervical phenotype, 31(72.1%), and they had ALS functional rating

206 score, median (IQR) of 27(25-32). (Table 2).

207

208 Table 2: Clinical characteristics of the ALS patients

Clinical Characteristics	Results
Disease Categories according to El scorial criteria, n (%)	
Possible	7(16.3)
Probable	8(18.6)
Definite	28(65.1)
Age of onset, Median (IQR)	57(46-64)
Phenotype according to the onset	
Bulbar	3(7)

Cervical	31(72.1)
Lumbar	2(4.7)
Mixed	7(16.3)
Disease duration, months, median (IQR)	6(5-10)
ALS function rating score, median (IQR)	27(25-32)

209

The median (IQR) CMAP amplitude of FDI, APB, and ADM, 2.8(0.8-5.3), 2.3(0.8-4.6), and 3.8(1.8-6.9) respectively were significantly low (p-value <0.001) than the healthy control. Among ALS patients amplitude of FDI and APB is lower than the amplitude of ADM. The median (IQR) of APB-FDI index, APB-ADM ratio and FDI-ADM ratio were 1.7(0.3-3.8), 0.6(0.3-1.1) and 0.8(0.4-1.1) were significantly lower than that of healthy control (p value<0.001, 0.016, 0.003 respectively). The ADM-APB ratio of 1.7(0.9-3.2) is significantly higher than the healthy control (p-value 0.016). (Table 3)

217 Table 3: Comparison of Electrophysiologic findings with the healthy controls and Hirayama

218 disease

Group I, n-30	СМАР	P value ^a	СМАР	P value ^b
	amplitude in		amplitude	
	mV		in mV	
	Group II, n=30		Group III,	
			n=30	
	Group I, n-30	amplitude in mV	amplitude in mV	amplitude in amplitude mV in mV Group II, n=30 Group III,

FDI (CMAP	2.8(0.8-5.3)	10.4(8.5-12.6)	< 0.001	1.3(0.9-4.9)	0.7
amplitude in					
mV)					
APB (CMAP	2.3(0.8-4.6)	7.9(6.5-9.3)	< 0.001	6.4(5.3-8.1)	< 0.001
amplitude in					
mV)					
ADM(CMAP	3.8(1.8-6.9)	9.7(6.2-11.8)	< 0.001	0.7(0.4-3.6)	0.003
amplitude in					
mV)					
APB-FDI	1.7(0.3-3.8)	9.9(6.1-13.1)	< 0.001	13.6(6.9-	< 0.001
Index ^c				15.7)	
APB/ADM	0.6(0.3-1.1)	0.8(0.7-1.2)	0.016	6.3(3.2-	< 0.001
				13,9)	
ADM/APB	1.7(0.9-3.2)	1.2(0.9-1.4)	0.016	0.2(0.1-0.3)	< 0.001
FDI/ADM	0.8(0.4-1.1)	1.2(0.9-1.4)	0.003	2(1.2-2.7)	0.002
a-comparison between ALS and healthy control					
b-Comparison between the ALS and Hirayama					

c- calculated with the formula APB FDI index (SI) = APB $_{CMAP}$ X FDI $_{CMAP}$ /ADM $_{CMAP}$

219 APB-FDI Index, FDI-ADM, and ADM-APB ratios.

220 CMAP amplitude of the FDI did not differ between the ALS and Hirayama patients (p-value 0.7).

221 Whereas the median (IQR) amplitude of the APB, 6.4(5.3-8.1), is significantly higher (p-value

222 <0.001), and the amplitude of ADM, 0.7(0.4-3.6) was significantly lower (p value0.003) in the

Hirayama than ALS.

- The median (IQR) of APB-FDI index, and FDI-ADM ratio was 13.6(6.9-15.7), and 2(1.2-2.7)
- were significantly higher in Hirayama group than that of healthy control (p value<0.001, <0.001,
- 0.002 respectively). Whereas the ADM-APB ratio of 0.2(0.1-0.3) is significantly lower in the
- Hirayama group than in the ALS group (p-value <0.001).
- There was no correlation between the disease severity of ALS and the APB-FDI index (r = -0.16,
- 229 p-value 0.28) (Supplement 1).

230 Comparison of ROC curves

To diagnose ALS, the APB-FDI Index, ADM-APB CMAP amplitude ratio, and FDI-ADM CMAP amplitude ratio are used with cutoff values of 4.27, 1.04, and 2.20, respectively. The APB-FDI Index has a high sensitivity and specificity with an AUC of 0.9. However, when differentiating Hirayama disease, the APB-FDI Index's cutoff value is higher at 11.6, but its specificity is lower at 0.7. In comparison, the APB-FDI Index is the most effective in diagnosing ALS compared to healthy individuals, but it has lower performance in differentiating Hirayama disease (Figure 2).

237 Figure 2: Comparison of the ROC curve and diagnostic performances of APB-FDI Index,

238 ADM-APB CMAP amplitude ratio, and FDI-ADM CMAP amplitude ratio

239 Comparison of IDI

- 240 We evaluated the prediction performance of the scoring systems by calculating IDIs,
- corresponding P values, and confidence intervals using 1000 times bootstrap resampling (Table
- 4). The IDI results showed that the APB-FDI Index was superior to the ADM-APB CMAP
- amplitude ratio and FDI-ADM CMAP amplitude ratio in healthy control and Hirayama although
- 244 p value is insignificant. The IDI for APB-FDI Index in comparison to ADM-APB CMAP
- amplitude ratio and FDI-ADM CMAP amplitude ratio was 0.55 (95% CI -0.661, -0.434;

- 246 p=0.481) and -0.55 (95% CI -0.658, -0.440; p=0.504), respectively in healthy control. In
- 247 Hirayama, the IDI for APB-FDI Index in comparison to ADM-APB CMAP amplitude ratio and
- 248 FDI-ADM CMAP amplitude ratio was -0.228 (95% CI -0.416, -0.015; p=0.487) and -0.368
- 249 (95% CI -0.541, -0.172; p=0.465), respectively.

250

251 Table 4. Pairwise comparison of IDIs in overall patients

Comparison of	IDI	95% CI of IDI	<i>P</i>-value of IDI
models			
(New model VS			
reference model)			
For healthy control			
FDI-APB index vs	-0.549	-0.658, -0.440	0.504
FDI-ADM ratio			
FDI-APB index vs	-0.545	-0.661, -0.434	0.481
ADM-APB			
FDI-ADM ratio vs	0.007	-0.035, 0.051	0.495
ADM-APB			
For Hirayama	1		
FDI-APB index vs	-0.368	-0.541, -0.172	0.465
FDI-ADM ratio			

FDI-APB index vs	-0.228	-0.416, -0.015	0.487
ADM-APB			
FDI-ADM ratio vs	0.133	-0.028, 0.262	0.495
ADM-APB			

252

253 Comparison of DCA curves

The results of DCA (Fig 3) demonstrate the clinical value of evaluating standardized net benefits 254 (sNBs) and risk threshold probabilities using the APB-FDI Index, ADM-APB CMAP amplitude 255 ratio, and FDI-ADM CMAP amplitude ratio. The sNBs of the APB-FDI Index were higher than 256 the extreme curve for healthy control and Hirayama when the range of risk threshold probabilities 257 was between 0.1 and 0.8. Compared to the ADM-APB CMAP and FDI-ADM CMAP amplitude 258 ratios, the APB-FDI Index had higher sNBs when the range of threshold probabilities was between 259 0.1 and 0.8, indicating its broad clinical utility. Optimal threshold probabilities were also 260 determined for each index using the Youden-Index (APB-FDI Index-0.72, ADM-APB CMAP 261 amplitude ratio-0.51, and FDI-ADM CMAP amplitude ratio-0.17), and the DCA results show that 262 263 the APB-FDI Index had higher sNBs than the other two ratios. Furthermore, the results and conclusions remained consistent for threshold probabilities between 0.45 and 0.80. 264

Figure 3. DCA curves of APB-FDI Index, ADM-APB CMAP amplitude ratio, and FDI-ADM

266 CMAP amplitude ratio

267

268

269

270

271 **Discussion:**

Our study confirms the split hand phenomenon in ALS patients, where the CMAP amplitude of 272 the ADM muscle is higher than that of the FDI and APB muscles. We measured this phenomenon 273 274 using the APB-FDI index, APB-ADM ratio, and FDI-ADM ratio. The cutoff values for these measurements are 4.27, 1.04, and 2.20, respectively. The APB-FDI index is more sensitive and 275 specific than the other two ratios, with a high AUC. However, for Hirayama disease, the APB-FDI 276 index cutoff value is 11.6, and it shows broad clinical utility with standardized net benefits 277 exceeding those of healthy controls and Hirayama patients when the risk thresholds are between 278 0.1 and 0.8. The IDI results indicate that the APB-FDI index is superior to the ADM-APB CMAP 279 amplitude ratio and FDI-ADM CMAP amplitude ratio in healthy controls and Hirayama patients. 280

This study was done among a small number of Bangladeshi ALS patients. NCS parameters may differ in demography and physical factors [20]; we cannot generalize the findings to different races, ages, and physical traits. It needs a multicentered and multinational prospective study to generalize.

In the present study, most ALS patients were 40 years or more, were generally male, and one-third had low body mass index. It is concordant with the demography and characteristics of ALS patients [2,4,21]. Most of the patients were a cervical onset phenotype. The predominant phenotype of ALS is bulbar in some studies [22], but in China dominant type is limb onset [23] in the case of sporadic ALS. As in this study, we studied hand cervical phenotype is frequent here. The patients with Hirayama were generally young and male, as found in the other studies [25,26].

The diagnosis of ALS is not always straightforward. There are no specific biomarkers of ALS, and
it is mainly diagnosed by criteria [27,28]. Accurate and early diagnosis is essential to increasing

the life expectancy of ALS patients [29]. The most used diagnostic criteria are the revised El Escorial criteria (rEEC) and Awaji criteria (AC), has sensitivity ranges from 40-70%, which increases with the progression of the disease [30]. Electrophysiology may help diagnose early ALS, as some electrophysiologic findings may appear earlier. Spilt hand phenomenon is commonly found across all stages and degrees of certainty of ALS [17,18].

298 The split hand phenomenon was first described by Wilbourn [10]. Satoshi Kuwabara [18], in their 299 research electro physiologically confirmed the preferential involvement of APB and FDI among ALS patients. In their study, they elucidate APB-ADM, FDI-ADM, and FDI-APB ratio. Among 300 301 the healthy control, the ratio of APB-ADM, FDI-ADM, and FDI-APB were 1(.3), 1.5(0.4), and 1.6(0.5), respectively [10]. Among the healthy subjects, the APB-ADM ratio was 0.8(0.7-1.2), 302 303 FDI-ADM was 1.2(0.9-1.4) [18], and both were almost similar. In our study The cutoff values, ADM-APB CMAP amplitude ratio, and FDI-ADM CMAP amplitude ratio are 4.27, 1.04, and 304 2.20, respectively. In this study, among the ALS patients, the APB-ADM value was 0.6(0.3-1.1), 305 and the FDI-ADM value was 0.8(0.4-1.1). The slight difference in the value might be due to 306 different reporting parameters. Moreover, they used the mean, whereas we used the median. And 307 in our study, the parameter was not normally distributed. They examined the ratio in lower motor 308 309 neuron disorders (LMND), cervical spondylotic amyotrophy (CSA), and polyneuropathy. They found that the findings are specific to ALS [18]. 310

We found few studies comparing the findings in Hirayama disease, which also presents with the small muscle of hand wasting [31]. This study also found that the split hand phenomenon is unique to ALS. The ratio of APB-ADM and FDI-ADM is reversed in Hirayama disease 6.3(3.2-13,9) and 2(1.2-2.7), respectively. In the case of Hirayama disease, the reverse split hand phenomenon is described in some studies. One study reported APB-ADM ratio 0.89 ± 0.98 [17]. APB amplitude

of Hirayama in our study was 6.4(5.3-8.1), similar to Kalita et al. [32]. They found CMAP ratio of
ADM-APB was 0.43 (0.29), and in our study, the median value was 0.2(0.1-0.3). Moreover, we
found wasting is more prominent in APB than in the FDI (.28 vs. 2.3).

In a study, an ADM-APB ratio >1.7 was found to be 51% sensitive and 99% sensitive [16]; in our study, we found the median ratio of 1.7 of (0.9-3.2), and a value >2.2 can diagnose ALS with 21%

321 sensitivity and 96% specificity.

322 The split hand index was first examined by Menon et al. [11]; they found the index in ALS was

323 3.5 ± 0.6 , SI cutoff value of 5.2 exhibiting a sensitivity of 74% and specificity of 80%. Our study

found that the median index was 1.7(0.3-3.8), and a cutoff value lower than 4.2 can diagnose ALS with 72% sensitivity and 100% specificity. In another study, the spilt hand index in Hirayama was found as 13.68 (9.39), whereas in our study, it was 13.6(6.9-15.7), and in ALS, they found it 2.13 (1.90) [32]. In this study, we affirmed the findings of other studies.

We evaluate which ratio performs better using indicators such as AUCs, IDIs, and DCAs. Based on DCA curve analysis, when the threshold probabilities were between 0.5 to 0.7, the order of performance was as follows: APB-FDI, FDI-ADM, and ADM-APB ratios. The APB-FDI index outperformed in all threshold probabilities, but FDI-ADM performed better than ADM-APB after threshold probabilities of 0.5.

Using decision curve analysis (DCA) has several advantages, including the consideration of patient and physician preferences and the use of a threshold probability metric. DCA helps in evaluating the benefits and harms associated with prediction models by assessing the value of correctly treating a positive case versus the risk of treating a false positive case. This makes it an essential

tool in clinical decision-making. When determining the risk threshold, a model with a higher
standardized net benefit (sNB) is deemed superior [32].

This study found that the APB-FDI index is more effective than other groups, with an AUC of 0.93 and a 95% confidence interval of 0.99-0.98. However, the AUC for FDI-ADM and ADM-APB were only 0.75 and 0.47, respectively. The Youden Index, which summarizes the receiver operating characteristic curve and places equal importance on sensitivity and specificity [33]., showed a high score of 0.72 for the APB-FDI index and a very low score of 0.18 for ADM-APB.

This study found that the overall IDA was less than 0, meaning the model's performance could have been better. Nevertheless, the APB-FDI index performed slightly better than the other two ratios, although the difference was not significant.

Our research has shown that the APB-FDI index is a more effective diagnostic tool than others, as it simultaneously considers all three muscles' involvement. Nevertheless, the APB-FDI test may be helpful in cases of severe muscle atrophy and concomitant entrapment neuropathy. It should still be routinely administered to evaluate small muscle wasting in the hands. This can help reduce unnecessary interventions for ALS patients, as research has shown that 5% of ALS patients undergo spinal surgery and 42% have lower back operations[35].

In this study, we provided a comprehensive analysis of the diagnostic performances. However, it is essential to note that our study had certain limitations. The small sample size and the crosssectional design are inherent limitations that may affect the generalizability of our findings. Additionally, as our data was obtained in real-time, the results may change throughout the disease. Future studies should establish whether this phenomenon is maintained in advanced disease stages through prospective analysis. Unfortunately, due to the limited sample size, we could not conduct

359 subgroup analysis. We recommend further studies comparing this phenomenon in different 360 phenotypes of ALS while also considering the duration of the disease. It should be noted that most 361 patients were evaluated during the routine diagnostic process.

362 **Conclusion**

APB-FDI Index, depicting the split hand phenomenon, is a highly sensitive and specific diagnostic marker and may be helpful in early and conflicting instances to diagnose ALS. Its diagnostic value is also higher than other diagnostic tests, like APB-ADM and FDI-ADM ratio, which reproduce the split hand phenomenon.

367 Acknowledgements

We are grateful to every patient who gave their valuable consent for participation in this study;without their help, it would be impossible to conduct this study.

References:

371	1.	van den Bos, M.A., Geevasinga, N., Higashihara, M., Menon, P. and Vucic, S., 2019.
372		Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological
373		techniques. International Journal of Molecular Sciences, 20(11), p.2818.

- 2. Coupe, C. and Gordon, P.H., 2013. Amyotrophic lateral sclerosis-clinical features,
 pathophysiology and management. *European Neurol Rev*, *8*, pp.38-44.
- Rossi, F. H., Franco, M. C., Estevez, A. G. . Pathophysiology of Amyotrophic Lateral
 Sclerosis. In: Estévez, A. G. , editor. Current Advances in Amyotrophic Lateral Sclerosis
 [Internet]. London: IntechOpen; 2013 [cited 2022 May 02]. Available from:
 https://www.intechopen.com/chapters/45326 doi: 10.5772/56562

380	4.	Gordon PH. Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features,
381		Pathophysiology, Management and Therapeutic Trials. Aging Dis. 2013 Oct 1;4(5):295-
382		310. doi: 10.14336/AD.2013.0400295. PMID: 24124634; PMCID: PMC3794725.
383	5.	Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of
384		amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic
385		Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular
386		Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop
387		contributors. J Neurol Sci. 1994 Jul;124 Suppl:96-107. doi: 10.1016/0022-510x(94)90191-
388		0. PMID: 7807156.
389	6.	Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research
390		Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis
391		of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord.
392		2000 Dec;1(5):293-9. doi: 10.1080/146608200300079536. PMID: 11464847.
393	7.	Agosta F, Al-Chalabi A, Filippi M, Hardiman O, Kaji R, Meininger V, Nakano I, Shaw P,
394		Shefner J, van den Berg LH, Ludolph A; WFN Research Group on ALS/MND. The El
395		Escorial criteria: strengths and weaknesses. Amyotroph Lateral Scler Frontotemporal
396		Degener. 2015 Mar;16(1-2):1-7. doi: 10.3109/21678421.2014.964258. Epub 2014 Dec 8.
397		PMID: 25482030.
398	8.	Ghasemi M. Amyotrophic lateral sclerosis mimic syndromes. Iran J Neurol. 2016 Apr
399		3;15(2):85-91. PMID: 27326363; PMCID: PMC4912674.
400	9.	Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, Cudkowicz M, Atassi N.
401		Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS).
402		Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):453-6. doi:

403 10.3109/21678421.2014.903974. Epub 2014 Jul 1. PMID: 24981792; PMCID:
404 PMC4433003.

- 405 10. Wilbourn AJ. The "split hand syndrome". Muscle Nerve. 2000 Jan;23(1):138. doi:
 406 10.1002/(sici)1097-4598(200001)23:1<138:aid-mus22>3.0.co;2-7. PMID: 10590421.
- 407 11. Menon P, Kiernan MC, Yiannikas C, Stroud J, Vucic S. Split-hand index for the diagnosis
 408 of amyotrophic lateral sclerosis. Clin Neurophysiol. 2013 Feb;124(2):410-6. doi:
 409 10.1016/j.clinph.2012.07.025. Epub 2012 Sep 25. PMID: 23017503.
- Lisen A, Kuwabara S. The split hand syndrome in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):399-403. doi: 10.1136/jnnp-2011-301456. Epub
 2011 Nov 19. PMID: 22100761.
- 413 13. Kuwabara S, Kanai K. [Altered axonal ion channel function in amyotrophic lateral
 414 sclerosis]. Brain Nerve. 2007 Oct;59(10):1109-15. Japanese. PMID: 17969351.
- 415 14. Weber M, Eisen A, Stewart H, Hirota N. The split hand in ALS has a cortical basis. J
 416 Neurol Sci. 2000 Nov 1;180(1-2):66-70. doi: 10.1016/s0022-510x(00)00430-5. PMID:
 417 11090867.
- 418 15. Benny R, Shetty K. The split hand sign. Ann Indian Acad Neurol. 2012 Jul;15(3):175-6.
 419 doi: 10.4103/0972-2327.99700. PMID: 22919187; PMCID: PMC3424792.
- 420 16. Corcia P, Bede P, Pradat P, *et al*.Split-hand and split-limb phenomena in amyotrophic
 421 lateral sclerosis: pathophysiology, electrophysiology and clinical manifestations. *Journal*422 *of Neurology, Neurosurgery & Psychiatry* 2021;**92**:1126-1130.
- 423 17. GALNARES-OLALDE, Javier A. López-Hernández, Juan C. Saráchaga-Adib, Jorge de.
 424 et al. Split hand phenomenon: An early marker for amyotrophic lateral sclerosis. *Rev. mex.*

425	neurocienc. [online]. 2021, vol.22, n.4, pp.141-145. Epub 30-Jul-2021. ISSN 2604-
426	6180. <u>https://doi.org/10.24875/rmn.20000135</u>
427	
428	18. Tashiro K, Kikuchi S, Itoyama Y et al., "Nationwide survey of juvenile muscular atrophy
429	of distal upper extremity (Hirayama disease) in Japan," Amyotrophic Lateral Sclerosis, vol.
430	7, no. 1, pp.38–45, 2006.
431	19. Kuwabara S, Sonoo M, Komori T, Shimizu T, Hirashima F, Inaba A, Misawa S, Hatanaka
432	Y; Tokyo Metropolitan Neuromuscular Electrodiagnosis Study Group. Dissociated small
433	hand muscle atrophy in amyotrophic lateral sclerosis: frequency, extent, and specificity.
434	Muscle Nerve. 2008 Apr;37(4):426-30. doi: 10.1002/mus.20949. PMID: 18236469.
435	20. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The
436	ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of
437	respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999 Oct
438	31;169(1-2):13-21. doi: 10.1016/s0022-510x(99)00210-5. PMID: 10540002.
439	21. Fong SY, Goh KJ, Shahrizaila N, Wong KT, Tan CT. Effects of demographic and physical
440	factors on nerve conduction study values of healthy subjects in a multi-ethnic Asian
441	population. Muscle Nerve. 2016 Aug;54(2):244-8. doi: 10.1002/mus.25029. Epub 2016
442	May 19. PMID: 26790132.
443	22. Mariosa D, Beard JD, Umbach DM, Bellocco R, Keller J, Peters TL, Allen KD, Ye W,
444	Sandler DP, Schmidt S, Fang F, Kamel F. Body Mass Index and Amyotrophic Lateral
445	Sclerosis: A Study of US Military Veterans. Am J Epidemiol. 2017 Mar 1;185(5):362-371.
446	doi: 10.1093/aje/kww140. PMID: 28158443; PMCID: PMC5860019.

447	23. Chen L, Zhang B, Chen R, Tang L, Liu R, Yang Y, Yang Y, Liu X, Ye S, Zhan S, Fan D.
448	Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J
449	Neurol Neurosurg Psychiatry. 2015 Oct;86(10):1075-81. doi: 10.1136/jnnp-2015-310471.
450	Epub 2015 Jun 29. PMID: 26124198.
451	24. Talman P, Duong T, Vucic S, et al. Identification and outcomes of clinical phenotypes in
452	amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron
453	Disease observational cohortBMJ Open 2016;6:e012054. doi: 10.1136/bmjopen-2016-
454	012054
455	25. Hirayama K. [Juvenile non-progressive muscular atrophy localized in the hand and
456	forearmobservations in 38 cases]. Rinsho Shinkeigaku. 1972 Jul;12(7):313-24. Japanese.
457	PMID: 4674765.
458	26. Zhou B, Chen L, Fan D, Zhou D. Clinical features of Hirayama disease in mainland China.
459	Amyotroph Lateral Scler. 2010;11(1-2):133-9. doi: 10.3109/17482960902912407. PMID:
460	19412815.
461	27. de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, Mills K, Mitsumoto
462	H, Nodera H, Shefner J, Swash M. Electrodiagnostic criteria for diagnosis of ALS. Clin
463	Neurophysiol. 2008 Mar;119(3):497-503. doi: 10.1016/j.clinph.2007.09.143. Epub 2007
464	Dec 27. PMID: 18164242.
465	28. Li TM, Swash M, Alberman E, Day SJ. Diagnosis of motor neuron disease by neurologists:
466	a study in three countries. J Neurol Neurosurg Psychiatry. 1991 Nov;54(11):980-3. doi:
467	10.1136/jnnp.54.11.980. PMID: 1800671; PMCID: PMC1014620.
468	29. Rooney J, Byrne S, Heverin M, Tobin K, Dick A, Donaghy C, et al. A multidisciplinary
469	clinic approach improves survival in ALS: a comparative study of ALS in Ireland and

470	Northern Ireland. Journal of neurology, neurosurgery, and psychiatry. 2015;86(5):496-
471	501. pmid:25550416

- 30. Bademain Jean Fabrice Ido, Imen Kacem, Mahamadi Ouedraogo, Amina Nasri, Saloua
 Mrabet, Amina Gargouri, Mouna Ben Djebara, Bawindsongré Jean Kabore, Riadh
 Gouider, "Sensitivity of Awaji Criteria and Revised El Escorial Criteria in the Diagnosis
 of Amyotrophic Lateral Sclerosis (ALS) at First Visit in a Tunisian Cohort", *Neurology Research*International, vol. 2021, Article
 ID 8841281, 6 pages, 2021. https://doi.org/10.1155/2021/8841281
- 31. Singh RJ, Preethish-Kumar V, Polavarapu K, Vengalil S, Prasad C, Nalini A. Reverse split
 hand syndrome: Dissociated intrinsic hand muscle atrophy pattern in Hirayama
 disease/brachial monomelic amyotrophy. Amyotroph Lateral Scler Frontotemporal
 Degener. 2017 Feb;18(1-2):10-16. doi: 10.1080/21678421.2016.1223140. Epub 2016 Aug
 30. PMID: 27575868.
- 32. Kalita J, Kumar S, Misra UK, Neyaz Z. Split hand index and ulnar to median ratio in
 Hirayama disease and amyotrophic lateral sclerosis. Amyotroph Lateral Scler
 Frontotemporal Degener. 2017 Nov;18(7-8):598-603. doi:
 10.1080/21678421.2017.1336561. Epub 2017 Jun 15. PMID: 28616933
- 33. Zhang Z, Rousson V, Lee WC, Ferdynus C, Chen M, Qian X, Guo Y; written on behalf of
 AME Big-Data Clinical Trial Collaborative Group. Decision curve analysis: a technical
 note. Ann Transl Med. 2018 Aug;6(15):308. doi: 10.21037/atm.2018.07.02. PMID:
 30211196; PMCID: PMC6123195.

- 491 34. Schisterman EF, Faraggi D, Reiser B, Hu J. Youden Index and the optimal threshold for
- 492 markers with mass at zero. Stat Med. 2008 Jan 30;27(2):297-315. doi: 10.1002/sim.2993.
- 493 PMID: 17624866; PMCID: PMC2749250.
- 494 35. Yoshor, D., Klugh, A., Appel, S. H. & Haverkamp, L. J. Incidence and characteristics of
- spinal decompression surgery after the onset of symptoms of amyotrophic lateral
 sclerosis. *Neurosurgery.* 57, 984–988 (2005).

497 **Supporting Information**

498 S1- Correlation between the disease severity of ALS assessed with ALS functional rating scale and

- the APB-FDI index
- 500
- 501
- 502
- 503
- 504
- 505
- 506
- 507
- 508
- 509
- - -
- 510




Figure 1

Figure 1: Patients and volunteer selection for this study

We screened 57 suspected patients with Motor Neuron Disease and included 43 patients after screening. We had 30 healthy volunteers and ten patients with Hirayama disease for comparison

medRxiv preprint doi: https://doi.org/10.1101/2023.08.04.23293649; this version posted August 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Figure 1 title




Figure 2

Figure 2: Comparison of the ROC curve and diagnostic performances of APB-FDI Index,

ADM-APB CMAP amplitude ratio, and FDI-ADM CMAP amplitude ratio

medRxiv preprint doi: https://doi.org/10.1101/2023.08.04.23293649; this version posted August 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Figure 2 title and legends




Figure 3